Figure 2.
Overall frequency of NHL subtypes after expert review, according to sampling procedures (n = 21 548). ALCL, anaplastic large cell lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; FL1,2,3A, grades 1, 2, and 3A follicular lymphoma; FL3B, grade 3B follicular lymphoma; HGBL, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; LPL/WD, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia; MCL, mantle cell lymphoma; ns, not significant; PTCL NOS, PTCL, not otherwise specified; TCRBCL, T-cell/histiocyte-rich B-cell lymphoma. Significance levels: ns, P > .05; ∗P ≤ .05; ∗∗P ≤ .01; ∗∗∗P ≤ .001; ∗∗∗∗P ≤ .0001.

Overall frequency of NHL subtypes after expert review, according to sampling procedures (n = 21 548). ALCL, anaplastic large cell lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; FL1,2,3A, grades 1, 2, and 3A follicular lymphoma; FL3B, grade 3B follicular lymphoma; HGBL, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements; LPL/WD, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia; MCL, mantle cell lymphoma; ns, not significant; PTCL NOS, PTCL, not otherwise specified; TCRBCL, T-cell/histiocyte-rich B-cell lymphoma. Significance levels: ns, P > .05; ∗P ≤ .05; ∗∗P ≤ .01; ∗∗∗P ≤ .001; ∗∗∗∗P ≤ .0001.

Close Modal

or Create an Account

Close Modal
Close Modal